Literature DB >> 35958186

Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study.

José Javier Morales-Núñez1, Mariel García-Chagollán1, José Francisco Muñoz-Valle1, Saúl Alberto Díaz-Pérez1, Paola Carolina Torres-Hernández2, Saraí Citlalic Rodríguez-Reyes3, Guillermo Santoscoy-Ascencio4, José Julio Sierra García de Quevedo4, Jorge Hernández-Bello1.   

Abstract

Purpose: Understanding the humoral immune response dynamics carried out by B cells in COVID-19 vaccination is little explored; therefore, we analyze the changes induced in the different cellular subpopulations of B cells after vaccination with BNT162b2 (Pfizer-BioNTech).
Methods: This prospective cohort study evaluated thirty-nine immunized health workers (22 with prior COVID-19 and 17 without prior COVID-19) and ten subjects not vaccinated against SARS-CoV-2 (control group). B cell subpopulations (transitional, mature, naïve, memory, plasmablasts, early plasmablast, and double-negative B cells) and neutralizing antibody levels were analyzed and quantified by flow cytometry and ELISA, respectively.
Results: The dynamics of the B cells subpopulations after vaccination showed the following pattern: the percentage of transitional B cells was higher in the prior COVID-19 group (p < 0.05), whereas virgin B cells were more prevalent in the group without prior COVID-19 (p < 0.05), mature B cells predominated in both vaccinated groups (p < 0.01), and memory B cells, plasmablasts, early plasmablasts, and double-negative B cells were higher in the not vaccinated group (p < 0.05).
Conclusion: BNT162b2 vaccine induces changes in B cell subpopulations, especially generating plasma cells and producing neutralizing antibodies against SARS-CoV-2. However, the previous infection with SARS-CoV-2 does not significantly alter the dynamics of these subpopulations but induces more rapid and optimal antibody production.
© 2022 Morales-Núñez et al.

Entities:  

Keywords:  B cell; BNT162b2; SARS-CoV-2; immunophenotype; vaccine

Year:  2022        PMID: 35958186      PMCID: PMC9361858          DOI: 10.2147/JIR.S374304

Source DB:  PubMed          Journal:  J Inflamm Res        ISSN: 1178-7031


  52 in total

Review 1.  The dynamics of the B follicle: understanding the normal counterpart of B-cell-derived malignancies.

Authors:  X Sagaert; B Sprangers; C De Wolf-Peeters
Journal:  Leukemia       Date:  2007-05-10       Impact factor: 11.528

2.  Differential transcriptome and development of human peripheral plasma cell subsets.

Authors:  Swetha Garimalla; Doan C Nguyen; Jessica L Halliley; Christopher Tipton; Alexander F Rosenberg; Christopher F Fucile; Celia L Saney; Shuya Kyu; Denise Kaminski; Yu Qian; Richard H Scheuermann; Greg Gibson; Iñaki Sanz; F Eun-Hyung Lee
Journal:  JCI Insight       Date:  2019-05-02

3.  Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion.

Authors:  Menno C van Zelm; Tomasz Szczepanski; Mirjam van der Burg; Jacques J M van Dongen
Journal:  J Exp Med       Date:  2007-02-20       Impact factor: 14.307

4.  Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses.

Authors:  Christoph Ruschil; Gisela Gabernet; Gildas Lepennetier; Simon Heumos; Miriam Kaminski; Zsuzsanna Hracsko; Martin Irmler; Johannes Beckers; Ulf Ziemann; Sven Nahnsen; Gregory P Owens; Jeffrey L Bennett; Bernhard Hemmer; Markus C Kowarik
Journal:  Front Immunol       Date:  2020-12-18       Impact factor: 7.561

5.  T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity.

Authors:  Jose L Casado; Johannes Haemmerle; Pilar Vizcarra; Mario Rodriguez-Dominguez; Tamara Velasco; Hector Velasco; Elena Centenera; Beatriz Romero-Hernandez; Marina Fernandez-Escribano; Alejandro Vallejo
Journal:  Clin Transl Immunology       Date:  2021-09-08

6.  Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.

Authors:  Victoria Hall; Sarah Foulkes; Ferdinando Insalata; Peter Kirwan; Ayoub Saei; Ana Atti; Edgar Wellington; Jameel Khawam; Katie Munro; Michelle Cole; Caio Tranquillini; Andrew Taylor-Kerr; Nipunadi Hettiarachchi; Davina Calbraith; Noshin Sajedi; Iain Milligan; Yrene Themistocleous; Diane Corrigan; Lisa Cromey; Lesley Price; Sally Stewart; Elen de Lacy; Chris Norman; Ezra Linley; Ashley D Otter; Amanda Semper; Jacqueline Hewson; Silvia D'Arcangelo; Meera Chand; Colin S Brown; Tim Brooks; Jasmin Islam; Andre Charlett; Susan Hopkins
Journal:  N Engl J Med       Date:  2022-02-16       Impact factor: 91.245

Review 7.  Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases.

Authors:  Yang Zhou; Ying Zhang; Jinming Han; Mengge Yang; Jie Zhu; Tao Jin
Journal:  J Transl Med       Date:  2020-03-17       Impact factor: 5.531

8.  Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.

Authors:  Federico Gobbi; Dora Buonfrate; Lucia Moro; Paola Rodari; Chiara Piubelli; Sara Caldrer; Silvia Riccetti; Alessandro Sinigaglia; Luisa Barzon
Journal:  Viruses       Date:  2021-03-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.